Boehringer Ingelheim and EFSD accepting diabetes grant applications

Pharmaceutical Company Product News

Boehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD) have opened submissions for diabetes research grant applications through a new joint project.

More than 2.5 million euros (2.1 million pounds) have been allocated over three years to support research projects targeting specific areas of interest, with applications being invited from non-profit institutions or groups of institutions ahead of the April 1st 2012 deadline.

Studies will need to focus on regulation of secretion and/or function of non-insulin peptides from the endocrine pancreas or mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "We are delighted to partner with the EFSD on this initiative and hope the grant encourages and supports new research in the field of diabetes."

This comes after the company signed an oncology-focused research service collaboration agreement with personalised medicines technology specialist Horizon Discovery last week.

See all the latest jobs in Pharmaceutical
Return to news

Tags